BTIG Reiterates Buy on Zevra Therapeutics, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 85.2%

Neg 0% Neu 0% Pos 85.2%

BTIG analyst Kambiz Yazdi reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $27.